Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

thanks to advancements in medical technology. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters ...

Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

“If approved, the Allurion Balloon could fill a significant gap ... additional trial data will be presented at a future medical meeting. The Company plans to submit the fourth and final module ...

“Data from the AUDACITY trial demonstrate the Allurion Balloon’s positive impact on weight loss and excellent safety record,” said Dr. Ram Chuttani, Chief Medical Officer and Founding ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Allurion Technologies, Inc. (ALUR) a Massachusetts-based medical device company Tuesday announced the issuance of a new U.S. patent ...

Based on the National Health and Morbidity Survey (NHMS) 2023 report, around 54.4 per cent of Malaysian adults were ...